RT Journal Article
SR Electronic
T1 Treatments administered to the first 9,152 reported cases of COVID19: a systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.07.20073981
DO 10.1101/2020.05.07.20073981
A1 Fajgenbaum, David C.
A1 Khor, Johnson S.
A1 Gorzewski, Alek
A1 Tamakloe, Mark-Avery
A1 Powers, Victoria
A1 Kakkis, Joseph J.
A1 Repasky, Mileva
A1 Taylor, Anne
A1 Beschloss, Alexander
A1 Hernandez-Miyares, Laura
A1 Go, Beatrice
A1 Nimgaonkar, Vivek
A1 McCarthy, Madison S.
A1 Kim, Casey J.
A1 Wing, Anna
A1 Mayer, Michael A.
A1 Pai, Ruth-Anne Langan
A1 Frankl, Sarah
A1 Fisher, Megan
A1 Germi, James
A1 Keyser, Cornelia A.
A1 Angelides, Philip
A1 Amurthur, Ashwin
A1 Jiang, Joanna
A1 Rasheed, Rozena
A1 Rodriguez-Lopez, Eric
A1 Napier, Erin
A1 Martins, Bruna
A1 Bambury, Stephen
A1 Gunderson, Karen
A1 Goodyear, Nick
A1 Mackay, Duncan
A1 Pierson, Sheila K.
YR 2020
UL http://medrxiv.org/content/early/2020/05/11/2020.05.07.20073981.abstract
AB The emergence of SARS-CoV-2/2019 novel coronavirus (COVID19) has created a global pandemic with no approved treatments or vaccines. Many treatments have already been administered to COVID19 patients but have not been systematically evaluated. We performed a systematic literature review to identify all treatments reported to be administered to COVID19 patients and assess time to clinically meaningful response for treatments with sufficient data. We searched PubMed, BioRxiv, MedRxiv, and ChinaXiv for articles reporting treatments for COVID19 patients published between 12/1/2019–3/27/2020. Data were analyzed descriptively. Of the 2,706 articles identified, 155 studies met inclusion criteria, comprising 9,152 patients from 14 different countries. The cohort was 45.4% female and 98.3% hospitalized and mean (SD) age was 44.4 years (SD 21.0). The most frequently administered drug classes were antivirals, antibiotics, and corticosteroids, and of the 115 reported drugs, the most frequently administered was combination lopinavir/ritonavir, which was associated with a time to clinically-meaningful response (complete symptom resolution or hospital discharge) of 11.7 (1.09) days. There was insufficient data to compare across treatments. A large number of treatments have been administered to the first 9,152 reported cases of COVID19. These data serve as the basis for an open-source registry of all reported treatments given to COVID19 patients. Further work is needed to prioritize drugs for investigation in well-controlled clinical trials and treatment protocols.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; DCF has received research funding from Janssen Pharmaceuticals and EUSA Pharma for the ACCELERATE Natural History Registry of Castleman disease; no other relationships or activities that could appear to have influenced the submitted workFunding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available at https://www.med.upenn.edu/CSTL/drug-repurposing.html.